Ophthalmology

Contacts lost in eye not such a rare thing—but 27?
Contacts lost in eye not such a rare thing—but 27?Patients with a contact lens lost in the eye are not a rare occurrence for ophthalmologists. However, 27 lenses at the same time may be another story! Another ophthalmologist shares his experience with a case involving 5 lenses within a patient's eye.
VMA associated with poor outcomes in anti-VEGF-treated patientsThe presence of vitreomacular adhesion (VMA) is associated with poorer, short-term anatomic, and functional outcomes in eyes with diabetic macular edema (DME) receiving anti-VEGF therapy, according to Márcio B. Nehemy, MD, PhD.
Infections with EK procedures risingDescemet’s stripping automated endothelial keratoplasty (DSAEK) appears to have a higher risk of postoperative fungal infections (predominantly Candida) when compared to penetrating keratoplasty (PK).
New IOL offers full-distance, good intermediate distancePresbyopia patients have changed. They are younger than ever, more active than ever before, and they have more treatment options than ever before.
IOL selection important in patients with retinal diseaseWhen dealing with patients with retinal disease, macular disease, or a meaningful risk of retinal detachment, certain types of IOLs should be avoided due to potential complications.
Teleglaucoma redefining role in future of blindness prevention'Teleglaucoma’ is feasible and can play a major role in blindness prevention. Telemedicine and teleglaucoma are going to be an important part of how physicians take care of patients in the United States and worldwide.
Glaucoma, dry eye drugs center of pharmaceutical opportunitiesThe pharma drought is coming to a close. After decades of same-old medications for glaucoma and ocular surface disease, a series of new agents with new mechanisms of action (MOA) are moving toward marketing approval.
Aerie’s focus on therapies that address cause of vision lossAerie Pharmaceuticals is developing the first novel mechanism of action for the treatment of glaucoma in over 20 years. The company is developing two products for the treatment of patients with glaucoma and ocular hypertension. One is an entirely new agent, netarsudil, the other is a combination of netarsudil plus latanoprost.
B + L places focus on innovation in pharma, surgical, vision careBausch + Lomb (B + L) is more than one of the oldest eye care companies in the industry. It is also one of the broadest, with portfolios in contact lenses, consumer eye products, cataract surgery, intraocular lenses, retina surgery, and a wide range of ophthalmic pharmaceutical products.
Novartis Alcon changes build better platform for ophthalmologyAlcon Laboratories pharmaceutical products have been moved into the Novartis Pharmaceutical Division. The switch means a sharper focus on research and development in ophthalmology as well as better access to Norvartis’ patient services and support capabilities.